{"id":"https://openalex.org/W4367054698","doi":"https://doi.org/10.1177/02698811231167852","title":"A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA B receptor, and morphine in recreational opioid users","display_name":"A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA B receptor, and morphine in recreational opioid users","publication_year":2023,"publication_date":"2023-04-26","ids":{"openalex":"https://openalex.org/W4367054698","doi":"https://doi.org/10.1177/02698811231167852","pmid":"https://pubmed.ncbi.nlm.nih.gov/37125424"},"language":"en","primary_location":{"id":"doi:10.1177/02698811231167852","doi":"https://doi.org/10.1177/02698811231167852","is_oa":false,"landing_page_url":"https://doi.org/10.1177/02698811231167852","pdf_url":null,"source":{"id":"https://openalex.org/S136368880","display_name":"Journal of Psychopharmacology","issn_l":"0269-8811","issn":["0269-8811","1461-7285"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Psychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082969445","display_name":"Mototsugu Ito","orcid":"https://orcid.org/0000-0003-2482-9019","observed_orcids":["https://orcid.org/0000-0003-2482-9019"]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mototsugu Ito","raw_affiliation_strings":["Development Project Management, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"],"raw_orcid":"https://orcid.org/0000-0003-2482-9019","affiliations":[{"raw_affiliation_string":"Development Project Management, Astellas Pharma Global Development, Inc., Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033386735","display_name":"Mark Walzer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Walzer","raw_affiliation_strings":["Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, IL, USA","Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]},{"raw_affiliation_string":"Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023739899","display_name":"Mary Beth Blauwet","orcid":"https://orcid.org/0000-0002-5719-7479","observed_orcids":["https://orcid.org/0000-0002-5719-7479"]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary Beth Blauwet","raw_affiliation_strings":["Biostatistics Department, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics Department, Astellas Pharma Global Development, Inc., Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071665980","display_name":"Anna Spence","orcid":"https://orcid.org/0009-0009-8221-2894","observed_orcids":["https://orcid.org/0009-0009-8221-2894"]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anna Spence","raw_affiliation_strings":["Biostatistics Department, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics Department, Astellas Pharma Global Development, Inc., Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082008264","display_name":"Nakyo Heo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nakyo Heo","raw_affiliation_strings":["Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, IL, USA","Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]},{"raw_affiliation_string":"Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000559517","display_name":"Debra Kelsh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128061","display_name":"Altasciences Clinical Research Vince & Associates","ror":"https://ror.org/02d950z41","country_code":"US","type":"other","lineage":["https://openalex.org/I4210128061"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Debra Kelsh","raw_affiliation_strings":["Altasciences, Clinical Kansas, Inc., Overland Park, KS, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Altasciences, Clinical Kansas, Inc., Overland Park, KS, USA","institution_ids":["https://openalex.org/I4210128061"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081277476","display_name":"Paul C. Blahunka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Blahunka","raw_affiliation_strings":["Employee of Astellas, Northbrook, IL, USA, at the time of the study"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Employee of Astellas, Northbrook, IL, USA, at the time of the study","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028059076","display_name":"Jay Erdman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jay Erdman","raw_affiliation_strings":["Development Project Management, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Development Project Management, Astellas Pharma Global Development, Inc., Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005708035","display_name":"Mohamad Nour Alsharif","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mohamad Nour Alsharif","raw_affiliation_strings":["Development Project Management, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Development Project Management, Astellas Pharma Global Development, Inc., Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004332028","display_name":"Gerard J. Marek","orcid":"https://orcid.org/0000-0001-8103-4306","observed_orcids":["https://orcid.org/0000-0001-8103-4306"]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]},{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gerard J Marek","raw_affiliation_strings":["Employee of Astellas, Northbrook, IL, USA, at the time of the study","Gilgamesh Pharmaceuticals Inc., New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Employee of Astellas, Northbrook, IL, USA, at the time of the study","institution_ids":["https://openalex.org/I4210165171"]},{"raw_affiliation_string":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA","institution_ids":["https://openalex.org/I4405267702"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5082969445"],"corresponding_institution_ids":["https://openalex.org/I4210165171"],"apc_list":{"value":4000,"currency":"USD","value_usd":4000},"apc_paid":null,"fwci":1.2739,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.7758346,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":97},"biblio":{"volume":"37","issue":"5","first_page":"449","last_page":"461"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.8999000191688538,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.8999000191688538,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11199","display_name":"Pain Management and Opioid Use","score":0.018799999728798866,"subfield":{"id":"https://openalex.org/subfields/2703","display_name":"Anesthesiology and Pain Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.016599999740719795,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gabab-receptors","display_name":"GABAB receptors","score":0.8460000157356262},{"id":"https://openalex.org/keywords/positive-allosteric-modulators","display_name":"positive allosteric modulators","score":0.9929999709129333},{"id":"https://openalex.org/keywords/morphine","display_name":"morphine","score":0.9929999709129333},{"id":"https://openalex.org/keywords/opioid-use-disorder","display_name":"opioid use disorder","score":0.9580000042915344},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8539999723434448},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9079999923706055},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7049999833106995},{"id":"https://openalex.org/keywords/respiratory-depression","display_name":"respiratory depression","score":0.8100000023841858},{"id":"https://openalex.org/keywords/opioid-withdrawal","display_name":"opioid withdrawal","score":0.609000027179718},{"id":"https://openalex.org/keywords/drug-abuse","display_name":"drug abuse","score":0.6340000033378601}],"concepts":[{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.6322857141494751},{"id":"https://openalex.org/C2776038425","wikidata":"https://www.wikidata.org/wiki/Q2649417","display_name":"Allosteric modulator","level":4,"score":0.6291731595993042},{"id":"https://openalex.org/C2777389121","wikidata":"https://www.wikidata.org/wiki/Q81225","display_name":"Morphine","level":2,"score":0.6136270761489868},{"id":"https://openalex.org/C166342909","wikidata":"https://www.wikidata.org/wiki/Q845326","display_name":"Allosteric regulation","level":3,"score":0.5403189659118652},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5204893946647644},{"id":"https://openalex.org/C2779886867","wikidata":"https://www.wikidata.org/wiki/Q421797","display_name":"Opioid receptor","level":4,"score":0.5198110342025757},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.49800682067871094},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4626999497413635},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4460000693798065},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.4076654314994812},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3758642077445984},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3323802351951599},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21703609824180603},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000701","descriptor_name":"Analgesics, Opioid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005680","descriptor_name":"gamma-Aminobutyric Acid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009020","descriptor_name":"Morphine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009025","descriptor_name":"Morpholines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009293","descriptor_name":"Opioid-Related Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018080","descriptor_name":"Receptors, GABA-B","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1177/02698811231167852","doi":"https://doi.org/10.1177/02698811231167852","is_oa":false,"landing_page_url":"https://doi.org/10.1177/02698811231167852","pdf_url":null,"source":{"id":"https://openalex.org/S136368880","display_name":"Journal of Psychopharmacology","issn_l":"0269-8811","issn":["0269-8811","1461-7285"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:37125424","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37125424","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of psychopharmacology (Oxford, England)","raw_type":"Randomized Controlled Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G929780922","display_name":"Evaluation of the Safety and Efficacy of a New Oral Small Molecule GABA-B Receptor Positive Allosteric Modulator (PAM) as an Add-on Maintenance Therapy for Opioid Use Disorder (OUD)","funder_award_id":"UG3DA051392","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"}],"funders":[{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":32,"referenced_works":["https://openalex.org/W1982312755","https://openalex.org/W1983696090","https://openalex.org/W2041102042","https://openalex.org/W2048575458","https://openalex.org/W2054545805","https://openalex.org/W2061118494","https://openalex.org/W2088639396","https://openalex.org/W2115681481","https://openalex.org/W2116251941","https://openalex.org/W2132974770","https://openalex.org/W2134458339","https://openalex.org/W2172107654","https://openalex.org/W2172240632","https://openalex.org/W2606895480","https://openalex.org/W2796165444","https://openalex.org/W2804283237","https://openalex.org/W2902748282","https://openalex.org/W2904830602","https://openalex.org/W2921255665","https://openalex.org/W2923332423","https://openalex.org/W2951382818","https://openalex.org/W2982110959","https://openalex.org/W2998813706","https://openalex.org/W3095492073","https://openalex.org/W3119480574","https://openalex.org/W3153286879","https://openalex.org/W3180298022","https://openalex.org/W4200337926","https://openalex.org/W4205090246","https://openalex.org/W4205462572","https://openalex.org/W4319216027","https://openalex.org/W4320921208"],"related_works":["https://openalex.org/W4319216027","https://openalex.org/W4320921208","https://openalex.org/W2998813706","https://openalex.org/W4237408013","https://openalex.org/W2020260704","https://openalex.org/W4404982734","https://openalex.org/W2328557209","https://openalex.org/W3021239827","https://openalex.org/W7160822861","https://openalex.org/W2055432693"],"abstract_inverted_index":{"Background:":[0],"Recent":[1],"increases":[2],"in":[3,17,50,235,245],"opioid":[4,8],"use":[5,9],"and":[6,32,45,106,111,250],"subsequent":[7],"disorder":[10],"are":[11],"a":[12,37,82,120,228],"major":[13],"public":[14],"health":[15],"crisis":[16],"the":[18,29,103,158],"United":[19],"States.":[20],"Aims:":[21],"This":[22],"phase":[23,206],"1":[24,207],"randomized,":[25],"placebo-controlled":[26],"study":[27],"investigated":[28],"safety,":[30,100],"tolerability,":[31],"pharmacokinetics":[33],"(PKs)":[34],"of":[35,48,86,108,127,170],"ASP8062,":[36],"\u03b3-aminobutyric":[38],"acid":[39],"B":[40],"receptor-positive":[41],"allosteric":[42],"modulator,":[43],"with":[44,65,165,174,221],"without":[46],"administration":[47],"morphine":[49,80,177,184,223],"participants":[51,78,129,246],"who":[52],"used":[53],"opioids":[54],"recreationally.":[55],"Methods:":[56],"Participants":[57],"were":[58,90,119,146,163,198],"randomly":[59],"assigned":[60],"(2:1)":[61],"to":[62,154,248],"daily":[63],"dosing":[64],"ASP8062":[66,134,175,182,249],"25":[67],"mg":[68],"or":[69,139,149,193,217,238,242],"placebo":[70,140,179],"on":[71,92],"days":[72,93],"1\u201310.":[73],"On":[74],"day":[75],"10,":[76],"all":[77],"received":[79,133],"as":[81,102],"single":[83],"oral":[84],"dose":[85],"45":[87],"mg;":[88],"assessments":[89],"performed":[91],"11\u201316.":[94],"The":[95],"primary":[96],"end":[97,117],"point":[98],"was":[99],"evaluated":[101],"nature,":[104],"frequency,":[105],"severity":[107],"adverse":[109,151,161,171,195,240],"events,":[110],"end-tidal":[112],"CO":[113],"2":[114],"levels.":[115],"PK":[116,201,219],"points":[118],"secondary":[121],"outcome":[122],"measure.":[123],"Results:":[124],"A":[125],"total":[126],"24":[128],"(aged":[130],"21\u201354":[131],"years)":[132],"(":[135,141],"n":[136,142],"=":[137,143],"16)":[138],"8).":[144],"There":[145,197],"no":[147,199],"deaths":[148],"serious":[150],"events":[152,162,172,241],"leading":[153],"treatment":[155],"discontinuation":[156],"during":[157],"study.":[159],"Most":[160],"mild,":[164],"numerically":[166],"lower":[167],"absolute":[168],"number":[169],"reported":[173],"plus":[176,180,183],"versus":[178],"morphine.":[181,251],"did":[185,210],"not":[186,211],"increase":[187,234],"respiratory":[188,243],"depression,":[189],"potential":[190],"drug":[191,236],"abuse-":[192,237],"withdrawal-related":[194,239],"events.":[196],"significant":[200],"interactions.":[202],"Conclusions:":[203],"In":[204],"this":[205],"study,":[208],"we":[209],"observe":[212],"any":[213],"unexpected":[214],"safety":[215],"signals":[216],"notable":[218],"interactions":[220],"concomitant":[222],"administration.":[224],"These":[225],"data":[226],"suggest":[227],"potentially":[229],"low":[230],"risk":[231],"for":[232],"an":[233],"distress":[244],"exposed":[247]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2023-04-27T00:00:00"}